Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

Telogen effluvium causes sudden hair loss, often due to stress or changes, and is treated by addressing the cause and offering support.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

TEDAR is crucial for skin cell differentiation and barrier formation.

In this study, hemoglobin levels were the only marker positively correlated with anagen hair ratios in patients with telogen effluvium, suggesting it may be a cost-effective initial test for management.

This study reports that oral rifampicin effectively treated the pustular lesions of tufted hair folliculitis in a 47-year-old woman, with no relapses after one year.

This research discusses a validated HPTLC method for simultaneously determining Tamsulosin Hydrochloride and Finasteride in bulk and pharmaceutical dosage forms but reports no new clinical results.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This paper reviews total skin electron therapy for mycosis fungoides and reports no new results; the authors focus on dose de-escalation's impact on toxicity and response rates.

This review discusses triboelectric nanogenerator (TENG) devices for body-integrated electrical stimulation therapy and suggests they may revolutionize personalized healthcare, but it reports no new clinical results.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

In this case report, a 14-year-old male with alopecia areata subtotalis and nail involvement showed significant improvement after 9 months of treatment with oral tofacitinib, including complete hair regrowth and nail texture improvement, though further studies are needed to confirm these findings.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This correspondence outlines a research aim to evaluate the usefulness of laboratory testing for telogen effluvium to assist in forming evidence-based treatment guidelines, though results are not provided in the abstract.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.

The LTF gene may help predict and manage nonspecific orbital inflammation.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This review highlights that Tremella fuciformis polysaccharide exhibits various bioactivities, such as antioxidant and immune-modulating effects, and explores its potential applications in food, pharmaceutical, and cosmetic industries.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

This study found that pediatric telogen effluvium in the US has varying triggers and management outcomes, with emotional stress and acute illness being the most common triggers.